SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 3rd, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 3, 2019, between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.DelMar Pharmaceuticals, Inc. • August 15th, 2019 • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.Common Stock Purchase Warrant • June 23rd, 2015 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date (as set forth above) and on or prior to the close of business on the [____] year anniversary of the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 13th, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 12, 2022, between Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
BERRY ONLY INC.Subscription Agreement • September 14th, 2012 • Berry Only Inc. • Specialty cleaning, polishing and sanitation preparations • Nevada
CLASS A/CLASS B] COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.DelMar Pharmaceuticals, Inc. • May 7th, 2015 • Pharmaceutical preparations • New York
THIS [CLASS A/CLASS B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date (as set forth above) and on or prior to the close of business on the [____] year anniversary of the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
DELMAR PHARMACEUTICALS, INC and MOUNTAIN SHARE Transfer, LLC, as Warrant Agent Warrant Agency Agreement Dated as of August [ ], 2019Warrant Agency Agreement • August 12th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of August [ ], 2019 (“Agreement”), between DelMar Pharmaceuticals, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), and Mountain Share Transfer, LLC (the “Warrant Agent”).
FORM OF WARRANT COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.DelMar Pharmaceuticals, Inc. • July 9th, 2015 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date (as set forth above) and on or prior to the close of business on the fifth anniversary of the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 28th, 2021 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 23, 2021, between Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SHARES of Common Stock, _________ PRE-FUNDED warrants (exercisable for _________ Shares) and _________ Warrants (exercisable for _________ Shares) of DELMAR PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 12th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
The undersigned, DelMar Pharmaceuticals, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of DelMar Pharmaceuticals, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representatives (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC and Dawson James Securities, Inc. are acting as representatives to the several Underwriters (each a “Representative” and collectively, the “Representatives” and if there are no Underwriters other than the Representatives, references to multiple Underwriters shall be disregarded and the term Representatives as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
PURCHASE AGREEMENTPurchase Agreement • August 3rd, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • Nevada
PURCHASE AGREEMENT (the “Agreement”), dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation (the “Company”), LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
COMMON STOCK PURCHASE WARRANT KINTARA THERAPEUTICS, INC.Common Stock Purchase • April 13th, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 14, 2022 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 14, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENT WARRANT TO PURCHASE SHARES OF COMMON STOCK KINTARA THERAPEUTICS, INC.Kintara Therapeutics, Inc. • October 24th, 2023 • Pharmaceutical preparations
THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [*], 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Placement Agent Agreement, dated as of [*], 2023 by and between the Company and A.G.P./Alliance Global Partners.
Kintara Therapeutics, Inc.Kintara Therapeutics, Inc. • April 13th, 2022 • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Jeffrey Bacha Chairman & CEO DelMar Pharmaceuticals, Inc. Suite 720 - 999 West Broadway Vancouver, British Columbia Canada V5Z 1K5 Dear Mr. Bacha:Letter Agreement • September 21st, 2017 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”) that Wainwright shall serve as the exclusive agent, advisor or underwriter in an offering (the “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of the Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in the Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connectio
WARRANT AGENT AGREEMENTWarrant Agent Agreement • May 12th, 2015 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Warrant Agent Agreement made as of May __, 2015, is between DelMar Pharmaceuticals, Inc. a Nevada corporation, with offices at 720-999 West Broadway, Vancouver, British Columbia, Canada V5Z1K5 (the “Company”), and Island Stock Transfer with offices at 15500 Roosevelt Blvd, Suite 301, Clearwater Florida 33760 (the “Warrant Agent”).
DELMAR PHARMACEUTICALS, INC. COMMON STOCK WARRANTDelMar Pharmaceuticals, Inc. • May 5th, 2016 • Pharmaceutical preparations
DelMar Pharmaceuticals, Inc., a Nevada corporation (the "Company"), hereby certifies that, as partial compensation for its services as advisor to the Company,________________________________________ or its registered assigns (the "Holder"), is entitled to purchase from the Company up to a total of ________ shares of common stock, par value $0.001 per share (the “Common Stock”) (each, a “Warrant” and collectively, the “Warrants,” and each such share of Common Stock, a "Warrant Share" and all such shares of Common Stock, the "Warrant Shares"), at any time and from time to time commencing 180 days from the Original Issue Date, and through and including ________ , 2021, the fifth anniversary of the Original Issue Date (the "Expiration Date"), and subject to the following terms and conditions:
DELMAR PHARMACEUTICALS, INC and MOUNTAIN SHARE Transfer, LLC, as Warrant Agent Warrant Agency Agreement Dated as of August 14, 2019Warrant Agency Agreement • August 15th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of August 14, 2019 (“Agreement”), between DelMar Pharmaceuticals, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), and Mountain Share Transfer, LLC (the “Warrant Agent”).
COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.DelMar Pharmaceuticals, Inc. • September 21st, 2017 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ___1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Kintara Therapeutics, Inc. COMMON STOCK SALES AGREEMENTSales Agreement • September 19th, 2023 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
DELMAR PHARMACEUTICALS, INC. DEALER-MANAGER AGREEMENTDealer-Manager Agreement • June 10th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This EMPLOYMENT AGREEMENT (this “Agreement”), dated April 8, 2016 and effective on the date of consummation of the initial closing of the private placement offering of the Company’s common stock (the “Effective Date”), is by and between ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”) and Steven J. Rychnovsky (the “Executive”).
INDEMNITY AGREEMENTIndemnity Agreement • June 25th, 2018 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This Indemnity Agreement (this “Agreement”) dated as of ___________ _____, _____, is made by and between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and _________________ (“Indemnitee”).
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: DELMAR PHARMACEUTICALS, INC., a Nevada corporation; ADGERO ACQUISITION CORP., a Delaware corporation; and ADGERO BIOPHARMACEUTICALS HOLDINGS, INC. a Delaware corporation Dated as of June 9, 2020Agreement and Plan of Merger and Reorganization • June 10th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 9, 2020, by and among DELMAR PHARMACEUTICALS, INC., a Nevada corporation (“Parent”), ADGERO ACQUISITION CORP., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”). Parent, Merger Sub and Company may each be referred to herein individually as a “Party” and collectively as the “Parties.” Certain capitalized terms used in this Agreement are defined in Exhibit A.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 3rd, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • Nevada
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
AGREEMENT AND PLAN OF MERGER by and among KINTARA THERAPEUTICS, INC., KAYAK MERGECO, INC. and TUHURA BIOSCIENCES, INC. Dated as of April 2, 2024Agreement and Plan of Merger • April 3rd, 2024 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of April 2, 2024, by and among Kintara Therapeutics, Inc., a Nevada corporation (which shall reincorporate as a Delaware corporation in connection with the consummation of the transactions contemplated hereby) (“Parent”), Kayak Mergeco, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and TuHURA Biosciences, Inc., a Delaware corporation (the “Company”).
NONQUALIFIED STOCK OPTION GRANT AGREEMENTNonqualified Stock Option Grant Agreement • May 15th, 2018 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”).
COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.DelMar Pharmaceuticals, Inc. • August 12th, 2019 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after August ___, 2019 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s ri
STRICTLY CONFIDENTIAL Jeffrey Bacha Chairman & CEO DelMar Pharmaceuticals, Inc. Suite 720 - 999 West Broadway Vancouver, British Columbia Canada V5Z 1K5 Dear Mr. Bacha:Letter Agreement • April 13th, 2017 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”) that Wainwright shall serve as the exclusive agent, advisor or underwriter in an offering (the “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of the Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in the Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connectio
COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.DelMar Pharmaceuticals, Inc. • August 15th, 2019 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that is 180 days from the effective date (“Effective Date”) of the Registration Statement as defined below (the “Initial Exercise Date”) and on or prior to the close of business on [ ], 20221 (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to [_____] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 21st, 2020 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Aegis Capital Corp., a New York corporation (“Aegis” or “Placement Agent”), a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”), shall be engaged by DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”) to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of shares (the “Shares”) of Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”). The Offering will consist of a minimum of 10,000 Shares ($10 million) (“Minimum Offering Amount”) and up to a maximum of 20,000 Shares ($20 million) (“Maximum Offering Amount”) which shall be offered on a “reasonable efforts, all or none” basis as to the Minimum Offering Amount and a “reasonable efforts” basis for all amounts in excess of the Minimum Offering Amount. In the event the Offering is oversubscribed, the Company and Placement A
STRICTLY CONFIDENTIAL Kintara Therapeutics, Inc. 12707 High Bluff Dr., Suite 200 San Diego, CA 92130 Attn: Saiid Zarrabian, Chief Executive Officer Dear Mr. Zarrabian:Letter Agreement • September 28th, 2021 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between Kintara Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwrig
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of March 1, 2018 (the “Effective Date”) is by and between ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”) and John Liatos (the “Employee”).
CONSULTING AGREEMENTConsulting Agreement • April 10th, 2015 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • British Columbia
DEL MAR PHARMACEUTICALS (BC) LTD., with a registered address of Suite 720 – 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5;
STOCKHOLDER SUPPORT AGREEMENTStockholder Support Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS STOCKHOLDER SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of [●], 2020, by and among DelMar Pharmaceuticals, Inc., a Nevada corporation (“Parent”), and each of the undersigned stockholders (each, a “Holder”) of Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”).
